Facioscapulohumeral muscular dystrophy

What is Facioscapulohumeral muscular dystrophy?

Facioscapulohumeral muscular dystrophy (FSHD) is a rare inherited disorder that causes progressive muscle weakness and wasting, primarily affecting the face, shoulder blades, and upper arms. Despite being one of the most common forms of muscular dystrophy, FSHD affects approximately 4-10 people per 100,000 worldwide, making it a rare disease that often goes undiagnosed for years. The condition is characterized by its distinctive pattern of muscle involvement and notable asymmetry, where one side of the body may be more severely affected than the other. While FSHD can significantly impact quality of life, many individuals maintain mobility and independence with proper management and support.

Key statistics

Prevalence: 4-10 per 100,000 people globally
Inheritance pattern: Autosomal dominant (95% of cases)
Age of onset: Typically teens to early adulthood, can occur at any age
Gender distribution: Affects males and females equally
Carrier frequency: Approximately 1 in 15,000-20,000 people

Symptoms

Common symptoms: Facial weakness, difficulty closing eyes completely, inability to whistle or smile symmetrically, shoulder blade winging, shoulder weakness, foot drop, difficulty raising arms overhead, sleep disturbances.

The progression of FSHD typically follows a characteristic pattern, though severity and timing vary significantly between individuals. Early symptoms often include subtle facial weakness that may go unnoticed initially. Patients may have difficulty closing their eyes completely during sleep, leading to dry eyes upon waking. The inability to whistle, drink through a straw, or blow up balloons becomes apparent as facial muscles weaken.

Submit Your Paper

Shoulder involvement manifests as prominent shoulder blade winging, where the shoulder blades protrude from the back like wings. Patients develop difficulty lifting objects overhead, combing their hair, or reaching high shelves. The distinctive asymmetrical pattern means one shoulder may be significantly more affected than the other.

Lower limb symptoms typically develop later, with foot drop being common. This causes difficulty lifting the front part of the foot, leading to a characteristic high-stepping gait to avoid tripping. Hip and thigh weakness may develop in more advanced cases, potentially affecting walking ability.

Additional symptoms can include hearing loss (particularly high-frequency), which occurs in about 75% of patients, and sleep disorders due to breathing muscle weakness or restless leg syndrome.

Causes and risk factors

FSHD is caused by genetic mutations affecting the DUX4 gene and the D4Z4 repeat region on chromosome 4. In healthy individuals, the DUX4 gene is normally silenced in most tissues. However, in FSHD, genetic changes lead to inappropriate expression of DUX4 in muscle cells, causing muscle damage and progressive weakness.

There are two main genetic subtypes. FSHD1 accounts for 95% of cases and is caused by deletions in the D4Z4 repeat region, leading to reduced D4Z4 repeat units (fewer than 11 repeats). FSHD2, representing about 5% of cases, results from mutations in the SMCHD1 gene or other epigenetic regulators, combined with specific genetic backgrounds.

The primary risk factor is having an affected parent, as FSHD follows an autosomal dominant inheritance pattern. This means each child of an affected parent has a 50% chance of inheriting the condition. However, about 10-30% of cases result from new (de novo) mutations, meaning they occur spontaneously without a family history.

Environmental factors do not cause FSHD, but physical trauma, intense exercise, or emotional stress may potentially trigger or accelerate symptom onset in genetically susceptible individuals.

Prevention

As FSHD is a genetic condition, there is no way to prevent the disorder itself. However, genetic counseling and testing can provide valuable information for family planning decisions. Individuals with a family history of FSHD can undergo genetic testing to determine if they carry the mutation before having children.

Preimplantation genetic diagnosis (PGD) is available for couples using in vitro fertilization who want to ensure their children do not inherit FSHD. Additionally, prenatal testing can detect FSHD mutations during pregnancy, though this raises complex personal and ethical considerations that should be discussed with genetic counselors.

For those already diagnosed, early intervention and preventive care can help minimize complications and maintain function longer. This includes regular monitoring for hearing loss, cardiac function, and respiratory capacity.

Complications

Without proper management, FSHD can lead to several serious complications. Progressive muscle weakness may eventually require mobility aids, with approximately 20% of patients becoming wheelchair-dependent by age 50. Severe facial weakness can impact speech clarity, eating, and facial expressions, affecting social interactions and communication.

Respiratory complications can develop due to weakness of breathing muscles, particularly the diaphragm. This may lead to sleep apnea, chronic fatigue, and in severe cases, respiratory failure requiring ventilatory support.

Cardiac complications occur in some patients, including arrhythmias and conduction defects that may require pacemaker implantation. Hearing loss, while not life-threatening, can significantly impact quality of life and communication.

Spinal complications include lordosis (excessive inward curvature of the lower back) due to weak abdominal muscles, and scoliosis in some cases. Joint contractures may develop from prolonged muscle weakness and immobility.

Psychosocial complications are common, including depression, anxiety, and social isolation related to physical limitations and changes in appearance.

Diagnosis

Diagnosing FSHD often involves a lengthy journey, with patients seeing multiple specialists before receiving an accurate diagnosis. The average time from symptom onset to diagnosis is 5-10 years, partly due to the condition’s rarity and variable presentation.

Clinical evaluation begins with detailed family and medical history, focusing on the characteristic pattern of muscle weakness. Physical examination assesses facial weakness, shoulder blade positioning, and muscle strength patterns.

Genetic testing is the gold standard for FSHD diagnosis. This includes Southern blot analysis or molecular combing to measure D4Z4 repeat lengths for FSHD1, and sequencing of SMCHD1 and other genes for FSHD2. Genetic testing has largely replaced muscle biopsy, which was previously used but is now rarely necessary.

Additional diagnostic tests include creatine kinase levels (typically normal or mildly elevated), electromyography (EMG) showing myopathic changes, and muscle imaging using MRI or ultrasound to assess the pattern of muscle involvement.

Audiometry testing should be performed to assess hearing loss, and cardiac evaluation including electrocardiogram and echocardiogram may be recommended.

Treatment

Currently, there is no cure for FSHD, and no FDA-approved disease-modifying treatments exist. Management focuses on maintaining function, preventing complications, and improving quality of life through a multidisciplinary approach.

Physical therapy is cornerstone treatment, emphasizing maintaining range of motion, preventing contractures, and optimizing remaining muscle function. Occupational therapy helps adapt daily activities and recommends assistive devices.

Pain management may involve acetaminophen, ibuprofen, or other anti-inflammatory medications. Some patients benefit from gabapentin or pregabalin for neuropathic pain.

Mobility aids including ankle-foot orthoses (AFOs) for foot drop, shoulder supports, and eventually wheelchairs or scooters may be necessary. Sleep disorders may require continuous positive airway pressure (CPAP) therapy or BiPAP ventilation.

Hearing aids or cochlear implants may be needed for hearing loss. Cardiac complications may require medications like metoprolol or pacemaker implantation.

Experimental treatments under investigation include myostatin inhibitors, DUX4 targeting therapies, and gene therapy approaches.

Prognosis

FSHD prognosis varies significantly between individuals, even within the same family. Many patients maintain relatively normal lifespans with good quality of life, particularly those with milder forms. The condition typically progresses slowly over decades, though periods of more rapid progression may occur.

Approximately 80% of patients remain ambulatory throughout their lives, while about 20% eventually require wheelchair assistance. Factors associated with more severe disease include earlier age of onset, larger D4Z4 deletions, and certain genetic backgrounds.

Life expectancy is generally normal for most patients, though severe cases with significant respiratory or cardiac involvement may have reduced longevity. The highly variable nature of FSHD means that prognosis must be individualized, and many patients exceed initial expectations with proper care and support.

Regular monitoring and early intervention for complications can significantly improve outcomes and maintain independence longer.

Quality of life

Living with FSHD requires adaptations but doesn’t preclude a fulfilling life. Many patients continue working, though job modifications or career changes may be necessary. Ergonomic adjustments, flexible schedules, and assistive technology can help maintain employment.

Exercise should be moderate and avoid overexertion, which may accelerate muscle damage. Swimming, walking, and gentle resistance training are often beneficial. Physical therapy guidance is essential for developing safe exercise routines.

Sleep quality may be impacted by breathing difficulties or restless legs. Sleep hygiene measures, proper positioning, and treatment of sleep apnea when present are important. Mental health support through counseling or support groups helps address depression, anxiety, and adjustment challenges.

Dietary considerations include maintaining healthy weight to reduce stress on weak muscles, and ensuring adequate nutrition for muscle health. Social connections and community involvement remain important for emotional wellbeing.

Home modifications such as ramps, grab bars, and lifting devices can enhance independence and safety.

Pregnancy and fertility

FSHD does not directly affect fertility in men or women. However, pregnancy requires special considerations due to the genetic nature of the condition and potential physical challenges.

Pregnant women with FSHD may experience increased fatigue and muscle weakness due to additional physical demands. Labor and delivery are generally safe, though cesarean section may be considered if respiratory or abdominal muscles are significantly weak.

Genetic counseling is crucial before pregnancy to discuss the 50% risk of passing FSHD to children and available options including preimplantation genetic diagnosis. There are no specific medication safety concerns during pregnancy as most FSHD management involves supportive care rather than medications.

Breastfeeding may be challenging if upper body weakness is severe, but adaptive techniques and support can help. Childcare may require additional assistance or adaptive equipment as children grow.

Children

Infantile FSHD is a severe early-onset form affecting fewer than 5% of patients, typically associated with very small D4Z4 repeat numbers (1-3 repeats). These children may present in the first years of life with facial weakness, hearing loss, and developmental delays.

More commonly, FSHD symptoms begin in adolescence or young adulthood. Children with FSHD may require educational accommodations, adaptive physical education, and psychological support to cope with progressive physical limitations during crucial developmental years.

Early intervention services, including physical and occupational therapy, can help maintain function and independence. Special attention to hearing screening is important, as hearing loss may impact speech and language development.

Genetic testing in children is generally recommended only after symptoms appear, as there are currently no preventive treatments for asymptomatic individuals.

When to see a doctor

Seek medical evaluation if you notice persistent facial weakness, difficulty closing eyes completely, prominent shoulder blade winging, or progressive weakness affecting daily activities. Family history of similar symptoms warrants genetic counseling.

Urgent medical attention is needed for sudden breathing difficulties, chest pain, irregular heartbeat, or significant swallowing problems. These may indicate cardiac or respiratory complications requiring immediate intervention.

Routine care should include regular monitoring with neurology, cardiology, and audiology as recommended by your healthcare team. Early intervention can prevent complications and maintain quality of life.

Regional context

Limited data exists on FSHD prevalence specifically in the Caucasus region (Georgia, Armenia, Azerbaijan) or broader Eastern Mediterranean area. The condition appears to occur worldwide across all ethnic groups, suggesting similar prevalence rates likely exist in these regions.

Local healthcare systems may have varying levels of awareness and diagnostic capabilities for rare neuromuscular conditions. The Georgian Medical Journal welcomes contributions from regional specialists and patient advocates to better understand FSHD prevalence and care challenges in the Caucasus region.

Establishing regional registries and specialist networks could improve diagnosis and care coordination for FSHD patients in this geographic area.

Research and clinical trials

Exciting research developments offer hope for future FSHD treatments. Several approaches are under investigation, including antisense oligonucleotides designed to reduce DUX4 expression, myostatin inhibitors to promote muscle growth, and gene therapy strategies.

Notable clinical trials include studies of losmapimod (a p38 MAPK inhibitor) and various DUX4-targeting therapies. Stem cell research and regenerative medicine approaches are also being explored.

Patients can find current clinical trials at ClinicalTrials.gov using search terms “FSHD” or “facioscapulohumeral.” The FSHD Society maintains updated information about research opportunities and trial enrollment.

Biomarker research aims to develop better measures of disease progression to accelerate drug development. Patient registries and natural history studies provide crucial data for advancing research.

Frequently asked questions

Is FSHD fatal?

FSHD is not typically fatal. Most patients have normal or near-normal life expectancy, though severe cases with significant respiratory or cardiac involvement may have reduced longevity.

Will my children definitely inherit FSHD?

Each child has a 50% chance of inheriting FSHD if one parent is affected. However, genetic counseling and testing options can provide more specific information for family planning.

Does exercise make FSHD worse?

Moderate exercise is generally beneficial, but excessive or high-intensity exercise may potentially accelerate muscle damage. Work with physical therapy to develop safe exercise routines.

Why did my symptoms start suddenly if this is genetic?

While the genetic predisposition is present from birth, symptoms may appear to start suddenly due to reaching a threshold of muscle damage or following triggers like stress, illness, or trauma.

Can FSHD affect my heart or breathing?

Yes, some patients develop cardiac arrhythmias or breathing difficulties due to respiratory muscle weakness. Regular monitoring helps detect and manage these complications early.

Support and resources

FSHD Society: www.fshdsociety.org – Primary patient advocacy organization providing research funding, patient support, and educational resources.

Muscular Dystrophy Association (MDA): www.mda.org – Offers clinics, support services, and equipment assistance.

Orphanet: www.orpha.net – Comprehensive rare disease information portal.

EURORDIS: www.eurordis.org – European rare disease advocacy organization.

National Organization for Rare Disorders (NORD): www.rarediseases.org – Patient assistance programs and advocacy.

World Muscle Society: www.worldmusclesociety.org – Professional organization advancing neuromuscular disease research.

Related conditions

Duchenne muscular dystrophy
Limb-girdle muscular dystrophy
Myotonic dystrophy
Spinal muscular atrophy
Scapuloperoneal myopathy

Sources: Orphanet (orpha.net), OMIM, GeneReviews (NCBI),

Licensed under CC BY 4.0. Free to share with attribution to GMJ News.

Sources: Orphanet (orpha.net), OMIM, GeneReviews (NCBI), WHO ICD-11, EULAR/ACR guidelines. Schema.org MedicalCondition structured data included.